|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGBL5 |
Gene summary for AGBL5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGBL5 | Gene ID | 60509 |
| Gene name | AGBL carboxypeptidase 5 | |
| Gene Alias | CCP5 | |
| Cytomap | 2p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q8NDL9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 60509 | AGBL5 | LZE4T | Human | Esophagus | ESCC | 4.46e-03 | 2.50e-01 | 0.0811 |
| 60509 | AGBL5 | LZE7T | Human | Esophagus | ESCC | 1.15e-05 | 3.88e-01 | 0.0667 |
| 60509 | AGBL5 | LZE8T | Human | Esophagus | ESCC | 1.78e-02 | 1.64e-01 | 0.067 |
| 60509 | AGBL5 | LZE22T | Human | Esophagus | ESCC | 4.70e-07 | 3.31e-01 | 0.068 |
| 60509 | AGBL5 | LZE24T | Human | Esophagus | ESCC | 1.84e-17 | 4.81e-01 | 0.0596 |
| 60509 | AGBL5 | P1T-E | Human | Esophagus | ESCC | 1.54e-04 | 1.45e-01 | 0.0875 |
| 60509 | AGBL5 | P2T-E | Human | Esophagus | ESCC | 1.21e-34 | 6.60e-01 | 0.1177 |
| 60509 | AGBL5 | P4T-E | Human | Esophagus | ESCC | 1.73e-05 | 1.45e-01 | 0.1323 |
| 60509 | AGBL5 | P5T-E | Human | Esophagus | ESCC | 1.20e-02 | 8.81e-02 | 0.1327 |
| 60509 | AGBL5 | P8T-E | Human | Esophagus | ESCC | 3.67e-07 | 1.08e-01 | 0.0889 |
| 60509 | AGBL5 | P9T-E | Human | Esophagus | ESCC | 1.42e-05 | 9.76e-02 | 0.1131 |
| 60509 | AGBL5 | P10T-E | Human | Esophagus | ESCC | 2.34e-22 | 3.69e-01 | 0.116 |
| 60509 | AGBL5 | P11T-E | Human | Esophagus | ESCC | 4.21e-08 | 3.44e-01 | 0.1426 |
| 60509 | AGBL5 | P12T-E | Human | Esophagus | ESCC | 1.09e-16 | 1.87e-01 | 0.1122 |
| 60509 | AGBL5 | P15T-E | Human | Esophagus | ESCC | 9.02e-15 | 3.57e-01 | 0.1149 |
| 60509 | AGBL5 | P16T-E | Human | Esophagus | ESCC | 1.08e-25 | 4.53e-01 | 0.1153 |
| 60509 | AGBL5 | P17T-E | Human | Esophagus | ESCC | 4.98e-03 | 1.96e-01 | 0.1278 |
| 60509 | AGBL5 | P20T-E | Human | Esophagus | ESCC | 3.11e-09 | 3.16e-01 | 0.1124 |
| 60509 | AGBL5 | P21T-E | Human | Esophagus | ESCC | 2.46e-18 | 3.40e-01 | 0.1617 |
| 60509 | AGBL5 | P22T-E | Human | Esophagus | ESCC | 5.12e-25 | 5.47e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:000961516 | Oral cavity | LP | response to virus | 143/4623 | 367/18723 | 7.42e-10 | 3.52e-08 | 143 |
| GO:005160711 | Oral cavity | LP | defense response to virus | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
| GO:014054611 | Oral cavity | LP | defense response to symbiont | 97/4623 | 265/18723 | 9.31e-06 | 1.74e-04 | 97 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGBL5 | SNV | Missense_Mutation | novel | c.2403N>T | p.Met801Ile | p.M801I | Q8NDL9 | protein_coding | tolerated_low_confidence(0.07) | benign(0) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| AGBL5 | SNV | Missense_Mutation | c.49N>C | p.Gly17Arg | p.G17R | Q8NDL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| AGBL5 | SNV | Missense_Mutation | novel | c.1631N>T | p.Pro544Leu | p.P544L | Q8NDL9 | protein_coding | tolerated(0.09) | probably_damaging(0.991) | TCGA-A2-A3XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
| AGBL5 | SNV | Missense_Mutation | c.610N>T | p.Arg204Cys | p.R204C | Q8NDL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AGBL5 | SNV | Missense_Mutation | novel | c.786N>A | p.Phe262Leu | p.F262L | Q8NDL9 | protein_coding | tolerated(0.27) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGBL5 | insertion | Frame_Shift_Ins | rs747733044 | c.1259_1260insC | p.Lys423GlnfsTer28 | p.K423Qfs*28 | Q8NDL9 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| AGBL5 | insertion | Frame_Shift_Ins | novel | c.664_665insAATCTATTCTAGGAAGCCACAAACTGGGGAACAA | p.Pro222GlnfsTer20 | p.P222Qfs*20 | Q8NDL9 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| AGBL5 | deletion | Frame_Shift_Del | rs754247845 | c.2553_2556delNNNN | p.Ser853ThrfsTer27 | p.S853Tfs*27 | Q8NDL9 | protein_coding | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| AGBL5 | insertion | Nonsense_Mutation | novel | c.907_908insCCTCCTTAACCTAACCCTTGTTTTCCCCCAGCTCTCAG | p.Arg303ProfsTer5 | p.R303Pfs*5 | Q8NDL9 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| AGBL5 | SNV | Missense_Mutation | rs747328031 | c.1628C>T | p.Pro543Leu | p.P543L | Q8NDL9 | protein_coding | tolerated(0.29) | benign(0.145) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |